PHXM - Phaxiam Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-12.72M

Cash

25.19M

Avg Qtr Burn

-5.741M

Short % of Float

0.90%

Insider Ownership

0.00%

Institutional Own.

6.46%

Qtr Updated

12/31/22

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PHAXIAM phages Details Endocarditis infections, Staph aureus	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Leukemia, Acute lymphoblastic leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Breast cancer, Triple-negative breast cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.